Your browser doesn't support javascript.
loading
The metabolomic signature of weight loss and remission in the Diabetes Remission Clinical Trial (DiRECT).
Corbin, Laura J; Hughes, David A; Bull, Caroline J; Vincent, Emma E; Smith, Madeleine L; McConnachie, Alex; Messow, Claudia-Martina; Welsh, Paul; Taylor, Roy; Lean, Michael E J; Sattar, Naveed; Timpson, Nicholas J.
Afiliación
  • Corbin LJ; MRC Integrative Epidemiology Unit at University of Bristol, Bristol, UK. laura.corbin@bristol.ac.uk.
  • Hughes DA; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. laura.corbin@bristol.ac.uk.
  • Bull CJ; MRC Integrative Epidemiology Unit at University of Bristol, Bristol, UK.
  • Vincent EE; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
  • Smith ML; MRC Integrative Epidemiology Unit at University of Bristol, Bristol, UK.
  • McConnachie A; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
  • Messow CM; MRC Integrative Epidemiology Unit at University of Bristol, Bristol, UK.
  • Welsh P; School of Translational Health Sciences, Dorothy Hodgkin Building, University of Bristol, Bristol, UK.
  • Taylor R; MRC Integrative Epidemiology Unit at University of Bristol, Bristol, UK.
  • Lean MEJ; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
  • Sattar N; Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.
  • Timpson NJ; Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.
Diabetologia ; 67(1): 74-87, 2024 Jan.
Article en En | MEDLINE | ID: mdl-37878066
ABSTRACT
AIMS/

HYPOTHESIS:

High-throughput metabolomics technologies in a variety of study designs have demonstrated a consistent metabolomic signature of overweight and type 2 diabetes. However, the extent to which these metabolomic patterns can be reversed with weight loss and diabetes remission has been weakly investigated. We aimed to characterise the metabolomic consequences of a weight-loss intervention in individuals with type 2 diabetes.

METHODS:

We analysed 574 fasted serum samples collected within an existing RCT (the Diabetes Remission Clinical Trial [DiRECT]) (N=298). In the trial, participating primary care practices were randomly assigned (11) to provide either a weight management programme (intervention) or best-practice care by guidelines (control) treatment to individuals with type 2 diabetes. Here, metabolomics analysis was performed on samples collected at baseline and 12 months using both untargeted MS and targeted 1H-NMR spectroscopy. Multivariable regression models were fitted to evaluate the effect of the intervention on metabolite levels.

RESULTS:

Decreases in branched-chain amino acids, sugars and LDL triglycerides, and increases in sphingolipids, plasmalogens and metabolites related to fatty acid metabolism were associated with the intervention (Holm-corrected p<0.05). In individuals who lost more than 9 kg between baseline and 12 months, those who achieved diabetes remission saw greater reductions in glucose, fructose and mannose, compared with those who did not achieve remission. CONCLUSIONS/

INTERPRETATION:

We have characterised the metabolomic effects of an integrated weight management programme previously shown to deliver weight loss and diabetes remission. A large proportion of the metabolome appears to be modifiable. Patterns of change were largely and strikingly opposite to perturbances previously documented with the development of type 2 diabetes. DATA

AVAILABILITY:

The data used for analysis are available on a research data repository ( https//researchdata.gla.ac.uk/ ) with access given to researchers subject to appropriate data sharing agreements. Metabolite data preparation, data pre-processing, statistical analyses and figure generation were performed in R Studio v.1.0.143 using R v.4.0.2. The R code for this study has been made publicly available on GitHub at https//github.com/lauracorbin/metabolomics_of_direct .
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 Límite: Humans Idioma: En Revista: Diabetologia Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 Límite: Humans Idioma: En Revista: Diabetologia Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido